<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05084963</url>
  </required_header>
  <id_info>
    <org_study_id>RVLO 121-04</org_study_id>
    <nct_id>NCT05084963</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis</brief_title>
  <official_title>A Phase 2a, Double-blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of IRL201104 in Adult Participants With Active Eosinophilic Esophagitis (EoE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Revolo Biotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Revolo Biotherapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to asses the efficacy, safety and tolerability of repeat doses&#xD;
      of IRL201104 in Adult Participants with Active Eosinophilic Esophagitis (EoE)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the peak esophageal intraepithelial eosinophil count at Week 4.</measure>
    <time_frame>4 weeks</time_frame>
    <description>The change from baseline in histologic eosinophil count in each treatment group will be summarized as the mean, standard deviation, median, minimum, and maximum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in Dysphagia Symptom Questionnaire (DSQ) score from baseline. The DSQ is used to measure the frequency and intensity of dysphagia. The DSQ scores can range from 0 to 84, with a lower score indicating less frequent or less severe dysphagia</measure>
    <time_frame>8 weeks</time_frame>
    <description>The change from baseline in DSQ score in each treatment group will be summarized as the mean, standard deviation, median, minimum, and maximum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving peak esophageal intraepithelial eosinophil count of &lt; 15 eos/hpf</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number and the proportion of participants with a histologic eosinophil count of &lt; 15 eos/hpf will be summarized for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Emergent Adverse Events</measure>
    <time_frame>8 weeks</time_frame>
    <description>All TEAEs will be summarized overall and for each body system and preferred term by treatment group, relationship to investigational product, and severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Blood pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Summary statistics, by and across randomized treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Pulse rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>summarized by treatment group at baseline and at each scheduled visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Oral body Temperature</measure>
    <time_frame>8 weeks</time_frame>
    <description>summarized by treatment group at baseline and at each scheduled visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Respiration rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>summarized by treatment group at baseline and at each scheduled visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Laboratory Data: Biochemistry</measure>
    <time_frame>8 weeks</time_frame>
    <description>Glucose, liver function tests, urea, and electrolytes will be analysed by summary statistics, by and across randomized treatment group at baseline and at subsequent scheduled visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Laboratory Data: Haematology</measure>
    <time_frame>8 weeks</time_frame>
    <description>Full blood count variables will be analysed by summary statistics, by and across randomized treatment group at baseline and at subsequent scheduled visits.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <arm_group>
    <arm_group_label>Arm 1: IRL201104 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IRL201104 IV on Days 0, 7, and 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: IRL201104 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IRL201104 IV on Days 0, 7, and 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo IV on Days 0, 7, and 14</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IRL201104</intervention_name>
    <description>lyophilised powder for reconstitution for IV dosing</description>
    <arm_group_label>Arm 1: IRL201104 Dose A</arm_group_label>
    <arm_group_label>Arm 2: IRL201104 Dose B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo for IRL201104</description>
    <arm_group_label>Arm 3: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 to 75 years old, inclusive, at the time of signing the informed consent form.&#xD;
&#xD;
          2. Documented diagnosis of EoE by endoscopy prior to screening. Note: Must include a&#xD;
             demonstration of intraepithelial eosinophilic infiltration (peak cell count ≥ 15&#xD;
             eos/hpf [400×]) from esophageal biopsy specimens from endoscopy.&#xD;
&#xD;
          3. History (by participant report) of on average at least 2 episodes of dysphagia (with&#xD;
             intake of solids off anti-inflammatory therapy) per week in the 4 weeks prior to&#xD;
             screening, and on average at least 2 episodes of documented dysphagia per week during&#xD;
             any 2 consecutive weeks (qualifying period) between screening and baseline; dysphagia&#xD;
             is defined as trouble swallowing solid food, or having solid food stick, by&#xD;
             participant report; and completed the DSQ on ≥ 70% of days during the qualifying&#xD;
             period prior to baseline (Visit 1).&#xD;
&#xD;
          4. Must remain on a stabilized diet for at least 6 weeks prior to screening and during&#xD;
             the course of the study; stable diet is defined as no initiation of single or multiple&#xD;
             elimination diets or reintroduction of previously eliminated food groups.&#xD;
&#xD;
          5. Must be willing and able to continue any dietary therapy and/or medical regimens&#xD;
             (including gastric acid suppression) in effect at the screening visit. There should be&#xD;
             no change to these regimens during the study participation.&#xD;
&#xD;
          6. Willing and able to comply with all clinic visits and study-related procedures.&#xD;
&#xD;
          7. Able to understand and complete study-related questionnaires.&#xD;
&#xD;
          8. Provide signed informed consent.&#xD;
&#xD;
          9. Esophagogastroduodenoscopy (EGD) with photographs performed at screening (qualifying&#xD;
             EGD), with a demonstration of intraepithelial eosinophilic infiltration (peak cell&#xD;
             count ≥15 eos/hpf) in at least 2 of the 3 biopsied esophageal regions (proximal, mid,&#xD;
             or distal).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior participation in an IRL201104 clinical study.&#xD;
&#xD;
          2. Has any current disease of the gastrointestinal tract (aside from EoE) that may&#xD;
             impact, in the investigator's opinion, the patient's EoE disease status. This&#xD;
             includes, but not limited to: eosinophilic gastritis, eosinophilic enteritis,&#xD;
             eosinophilic duodenitis, eosinophilic colitis, or proctitis; inflammatory bowel&#xD;
             disease; or celiac disease.&#xD;
&#xD;
          3. Has other causes of esophageal eosinophilia or the following diseases:&#xD;
             hypereosinophilic syndromes, Churg-Strauss vasculitis (eosinophilic granulomatosis&#xD;
             with polyangiitis), or peripheral blood absolute eosinophil count of &gt; 1500&#xD;
             eosinophils/μL.&#xD;
&#xD;
          4. Has presence of oral or esophageal mucosal infection of any type.&#xD;
&#xD;
          5. Has any condition affecting the esophageal mucosa or altering esophageal motility&#xD;
             other than EoE.&#xD;
&#xD;
          6. History of achalasia, active Helicobacter pylori infection, Crohn's disease,&#xD;
             ulcerative colitis, celiac disease, and prior esophageal surgery (with the exception&#xD;
             of a surgical repair of an EoE complication).&#xD;
&#xD;
          7. Any esophageal stricture unable to be passed with a standard, diagnostic, adult (9 to&#xD;
             10 mm) upper endoscope or any critical esophageal stricture that requires dilation at&#xD;
             screening; or dilation within 2 months prior to screening.&#xD;
&#xD;
          8. On a pure liquid diet or any mouth or dental condition that prevents normal eating.&#xD;
&#xD;
          9. Has initiated, discontinued, or changed dosage regimen of PPIs within the 4 weeks&#xD;
             prior to the qualifying EGD, between the qualifying EGD and baseline visit (Visit 1),&#xD;
             or anticipates changes in the use of PPI during the study. PPI must remain constant&#xD;
             throughout the study.&#xD;
&#xD;
         10. History of bleeding disorders or esophageal varices.&#xD;
&#xD;
         11. Use of anticoagulants within 2 weeks prior to screening. Participants should not stop&#xD;
             these agents solely to become eligible for entry into this study.&#xD;
&#xD;
         12. Treatment with an investigational drug within 2 months or within 5 half-lives (if&#xD;
             known), whichever is longer, prior to screening.&#xD;
&#xD;
         13. Use of systemic corticosteroids within 3 months or swallowed topical corticosteroids&#xD;
             within 6 weeks prior to screening.&#xD;
&#xD;
         14. Treatment with oral immunotherapy (OIT) within 6 months prior to screening.&#xD;
&#xD;
         15. Allergen immunotherapy (sublingual immunotherapy [SLIT] and/or subcutaneous&#xD;
             immunotherapy [SCIT]), unless on a stable dose for at least 1 year prior to screening.&#xD;
&#xD;
         16. The following treatments within 3 months before the screening visit, or any condition&#xD;
             that, in the opinion of the investigator, is likely to require such treatment(s)&#xD;
             during the study:&#xD;
&#xD;
             Systemic immunosuppressive/immunomodulating drugs (eg, omalizumab, cyclosporine,&#xD;
             mycophenolate-mofetil, interferon [IFN]γ, Janus kinase inhibitors, azathioprine,&#xD;
             methotrexate, and other biologics that are ongoing [eg, dupilumab, benralizumab,&#xD;
             mepolizumab, or vedolizumab]).&#xD;
&#xD;
         17. Diagnosed with active parasitic infection; or suspected parasitic infection, unless&#xD;
             clinical and (if necessary) laboratory assessments have ruled out active infection&#xD;
             before randomization.&#xD;
&#xD;
         18. Chronic or acute infection requiring treatment with systemic antibiotics, antivirals,&#xD;
             or antifungals within 1 month prior to screening.&#xD;
&#xD;
         19. Use of oral antibiotics/anti-infectives within 2 weeks prior to screening.&#xD;
&#xD;
         20. Known or suspected immunosuppression, including history of invasive opportunistic&#xD;
             infections (eg, tuberculosis, non-tuberculous mycobacterial infections,&#xD;
             histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis)&#xD;
             despite infection resolution, or otherwise recurrent infections of abnormal frequency,&#xD;
             or prolonged infections suggesting an immunocompromised status, as judged by the&#xD;
             investigator.&#xD;
&#xD;
         21. Known history of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
         22. Positive or indeterminate hepatitis B surface antigen (HBsAg) or hepatitis C antibody&#xD;
             at screening.&#xD;
&#xD;
         23. Moderate or severe renal impairment (eGFR &lt;60 mL/min/1.73 m2) or end stage renal&#xD;
             disease.&#xD;
&#xD;
         24. Elevated transaminases (alanine aminotransferase [ALT] and/or aspartate&#xD;
             aminotransferase [AST]) &gt; 3 times the upper limit of normal (ULN) at screening.&#xD;
&#xD;
         25. History of malignancy within 5 years prior to screening, except completely treated in&#xD;
             situ carcinoma of the cervix and completely treated and resolved nonmetastatic&#xD;
             squamous or basal cell carcinoma of the skin.&#xD;
&#xD;
         26. Any other medical or psychological condition including relevant laboratory&#xD;
             abnormalities at screening that, in the opinion of the investigator, suggest a new&#xD;
             and/or insufficiently understood disease, may present an unreasonable risk to the&#xD;
             participant as a result of his/her participation in this clinical study, may make the&#xD;
             participant's participation unreliable, or may interfere with study assessments. The&#xD;
             specific justification for participants excluded under this criterion will be noted in&#xD;
             study documents (eg, chart notes, electronic case report form). These may include&#xD;
             participant-reported alcohol or drug abuse and severe concomitant illness(es).&#xD;
&#xD;
         27. Planned or anticipated use of any prohibited medications and procedures (as described&#xD;
             in the exclusion criteria) during study treatment.&#xD;
&#xD;
         28. Treatment with a live (attenuated) vaccine within 3 months prior to screening and/or&#xD;
             treatment of a killed vaccine within 30 days prior to screening, until the end of the&#xD;
             study with the exception of a coronavirus disease of 2019 (COVID-19) vaccine, as&#xD;
             described in Section 9.2.1.&#xD;
&#xD;
         29. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed&#xD;
             during the study.&#xD;
&#xD;
         30. Women unwilling to use adequate birth control, if of reproductive potential* and&#xD;
             sexually active. Adequate birth control is defined as agreement to consistently&#xD;
             practice an effective and accepted method of contraception throughout the duration of&#xD;
             the study and for 30 days after the last dose of study treatment. These include:&#xD;
             hormonal contraceptives, intrauterine device, or double barrier contraception (ie,&#xD;
             condom and diaphragm), or male partner with documented vasectomy.&#xD;
&#xD;
               -  For females, menopause is defined as at least 12 consecutive months without&#xD;
                  menses; to include laboratory confirmation of post-menopausal status (ie, a&#xD;
                  follicle stimulating hormone (FSH) of 2.25 U/mL must be documented).&#xD;
                  Hysterectomy, bilateral oophorectomy, or bilateral tubal ligation must be&#xD;
                  documented, as applicable; if documented, women with these conditions are not&#xD;
                  required to use additional contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Myers, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer, Revolo Biotherapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>+ 1.415.728.9922</phone>
    <email>clinicaltrials@revolobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Preferred Research Partners, Inc.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Watson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IMMUNOe Research Centers</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Collins</last_name>
      <phone>303-771-9000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute, Inc.</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34653</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knox</last_name>
      <phone>727-835-3261</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute, Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seela</last_name>
      <phone>727-835-3261</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>WR-Mount Vernon Clinical Research, LLC</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Schmeck</last_name>
      <phone>404-843-4400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hoover</last_name>
      <phone>319-335-9767</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tandem Clinical Research, LLC</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Durr</last_name>
      <phone>504-934-8086</phone>
      <email>info@tandemclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leung</last_name>
      <phone>617-636-5114</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuan</last_name>
      <phone>617-726-8705</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Revive Research Institute, Inc.</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grewal</last_name>
      <phone>313-662-2235</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Health / Division of Allergy &amp; Immunology</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ponda</last_name>
      <phone>516-622-5070</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Watts</last_name>
      <phone>919-843-0821</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Great Lakes Gastroenterology Research, LLC</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Khatami</last_name>
      <phone>440-205-1225</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>WR-ClinSearch, LLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leathers</last_name>
      <phone>423-698-4584</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tri-Cities Gastroenterology (CTMX)</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Powers</last_name>
      <phone>423-279-1404</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inquest Clinical Research</name>
      <address>
        <city>Baytown</city>
        <state>Texas</state>
        <zip>77521</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mehkri</last_name>
      <phone>832-606-2053</phone>
      <email>InquestClinical@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research</name>
      <address>
        <city>Riverton</city>
        <state>Utah</state>
        <zip>84065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cappello</last_name>
      <phone>385-423-4066</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Holman</last_name>
      <phone>801-585-9155</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 30, 2021</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EoE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

